WallStSmart

Indivior PLC Ordinary Shares (INDV)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 157% more annual revenue ($3.18B vs $1.24B). UTHR leads profitability with a 41.9% profit margin vs 17.0%. INDV trades at a lower P/E of 17.9x. UTHR earns a higher WallStSmart Score of 67/100 (B-).

INDV

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 8.5Value: 8.3Quality: 5.0

UTHR

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 9.0Value: 10.0Quality: 7.8
Piotroski: 5/9Altman Z: 7.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INDVUndervalued (+55.6%)

Margin of Safety

+55.6%

Fair Value

$76.75

Current Price

$30.26

$46.49 discount

UndervaluedFair: $76.75Overvalued
UTHRUndervalued (+62.9%)

Margin of Safety

+62.9%

Fair Value

$1282.02

Current Price

$541.60

$740.42 discount

UndervaluedFair: $1282.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INDV3 strengths · Avg: 8.7/10
Operating MarginProfitability
37.1%10/10

Strong operational efficiency at 37.1%

P/E RatioValuation
17.9x8/10

Attractively priced relative to earnings

Revenue GrowthGrowth
19.7%8/10

19.7% revenue growth

UTHR4 strengths · Avg: 9.5/10
Profit MarginProfitability
41.9%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
45.0%10/10

Strong operational efficiency at 45.0%

Altman Z-ScoreHealth
7.3010/10

Safe zone — low bankruptcy risk

EPS GrowthGrowth
24.5%8/10

Earnings expanding 24.5% YoY

Areas to Watch

INDV2 concerns · Avg: 3.0/10
EPS GrowthGrowth
3.8%4/10

3.8% earnings growth

Free Cash FlowQuality
$-245.00M2/10

Negative free cash flow — burning cash

UTHR1 concerns · Avg: 4.0/10
PEG RatioValuation
2.184/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : INDV

The strongest argument for INDV centers on Operating Margin, P/E Ratio, Revenue Growth. Profitability is solid with margins at 17.0% and operating margin at 37.1%. Revenue growth of 19.7% demonstrates continued momentum.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.

Bear Case : INDV

The primary concerns for INDV are EPS Growth, Free Cash Flow.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio.

Key Dynamics to Monitor

INDV profiles as a growth stock while UTHR is a mature play — different risk/reward profiles.

INDV carries more volatility with a beta of 1.19 — expect wider price swings.

INDV is growing revenue faster at 19.7% — sustainability is the question.

UTHR generates stronger free cash flow (173M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (67/100 vs 62/100), backed by strong 41.9% margins. INDV offers better value entry with a 55.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Indivior PLC Ordinary Shares

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?